Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases.
Experiments were designed to examine whether local cytokine therapy of subcutaneous (s.c.) tumours results in inhibition of their lung metastases. Moderately immunogenic, major histocompatibility complex (MHC) class I and II negative. B7 negative, metastasizing murine carcinoma MK16 transplantable in syngeneic mice was obtained by co-transfection of human papilloma virus type 16 (HPV 16) E6/E7 and activated H-ras oncogene plasmid DNA into C57BL/6 kidney cells. After s.c. transplantation of the malignantly converted MK16 cells, the majority of the transplanted mice developed lung metastases; the number and size of the lung metastases increased with the increasing size of the s.c. tumour. Therapy of 5-day MK16 tumours by peritumoral administration of recombinant interleukin-2 (IL-2) and recombinant interleukin-12 (IL-12) inhibited growth of the s.c. MK16 tumour transplants and reduced the number of MK16 lung metastases. To investigate the antimetastatic effect of IL-2 and IL- 12 in a clinically more relevant setting, surgical minimal residual tumour disease was utilized. Subcutaneously growing MK16 carcinomas, 8-12 mm in diameter, were removed on day 30 and the operated mice were injected with IL-2 or IL- 12 on days 35-39 and 42-46 at the site of the operation. Treatment with IL-2 significantly reduced the percentage of MK16 tumour recurrences as well as the number of lung metastases, whereas the effect of IL- 12 was substantially weaker and statistically insignificant.
Mikysková
R
R
Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague.
Bubenik
J
J
Mendoza
L
L
Vonka
V
V
Smahel
M
M
Símová
J
J
Jandlová
T
T
D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018122:B7-1 Antigen / Q000378:metabolism; D051940:B7-2 Antigen; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary / Q000821:virology; D002455:Cell Division / Q000187:drug effects; D002461:Cell Line, Transformed; D005260:Female; D006649:Histocompatibility Antigens / Q000378:metabolism; D018664:Interleukin-12 / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008562:Membrane Glycoproteins / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D030361:Papillomavirus Infections / Q000188:drug therapy* / Q000473:pathology; D014412:Tumor Virus Infections / Q000188:drug therapy* / Q000473:pathology
D015703:Antigens, CD; D000970:Antineoplastic Agents; D018122:B7-1 Antigen; D051940:B7-2 Antigen; C497965:Cd86 protein, mouse; D006649:Histocompatibility Antigens; D007376:Interleukin-2; D008562:Membrane Glycoproteins; D018664:Interleukin-12